Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight [Yahoo! Finance]
Lantheus Holdings, Inc. (LNTH)
Last lantheus holdings, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.lantheus.com/investor-relations
Company Research
Source: Yahoo! Finance
This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness of radioligand therapies, the increasing number of radioligand therapies that are under clinical trials including Novartis (177Lu-PSMA-617, 225Ac - PSMA - 617, 177Lu-NNS309, 177Lu-NeoB, AAA614, and ESP359), Curium Pharma (177Lu-PSMA-I&T), Lantheus and Eli Lilly and Company (Lu-PNT2002 and LNTH-1095), Fusion Pharmaceuticals and AstraZeneca (FPI-2265), Clarity Pharmaceuticals (67CU SAR-BBN and 64Cu-SAR-BBN), and others. LAS VEGAS March 12, 2026 /PRNewswire/ -- DelveInsight's Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Breast cancer, Extensive-stage small cell lung cancer (ES-SCLC), Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Follicular Lymphoma, Glioblastoma multiforme,
Show less
Read more
Impact Snapshot
Event Time:
LNTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LNTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LNTH alerts
High impacting Lantheus Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
LNTH
News
- Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
- Lantheus says FDA extended review period for radioactive diagnostic kit [Seeking Alpha]Seeking Alpha
- Lantheus (LNTH) had its "outperform" rating reaffirmed by William Blair.MarketBeat
- Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs) [Yahoo! Finance]Yahoo! Finance
- US FDA extends review of Lantheus' diagnostic imaging kit by three months [Yahoo! Finance]Yahoo! Finance
LNTH
Earnings
- 2/26/26 - Beat
LNTH
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/20/26 - Form ARS
- 3/20/26 - Form DEFA14A
- LNTH's page on the SEC website